This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an international phase 3 trial.

"Our findings have the potential to influence the standard of care for patients with very high-risk prostate cancer worldwide," said Dr. Tamim Niazi, associate professor in McGill University's Department of Oncology and principal investigator at the Lady Davis Institute for Medical Research of the Jewish General Hospital University Health Centre. "If supported by longer-term data, this approach offers a meaningful opportunity to extend the time patients live without cancer progression."

Niazi co-chaired the trial, which was led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

The interim results were presented at the Presidential Symposium of the European Society for Medical Oncology (ESMO) Congress in Madrid, a session reserved for studies with the potential to change clinical practice.

Prostate cancer is the most commonly diagnosed cancer among Canadian men. An estimated 29,300 new cases and 5,300 deaths are expected in 2026.

While radiation therapy combined with androgen deprivation therapy can be effective, a meaningful percentage of patients with very high-risk features still see their cancer return or spread. The patients enrolled in this study were at higher risk of cancer recurrence.

Researchers tested whether adding darolutamide (Nubeqa), a drug that blocks hormone signals that fuel prostate cancer growth, to standard androgen deprivation therapy could improve outcomes for patients at high risk of recurrence.

Source link